The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Therapeutic Pipeline Program, 2013Exenatide as a Treatment for Patients with Parkinson’s Disease
Objective/Rationale:
Laboratory data from several teams have indicated potential beneficial effects of the drug Exenatide on the survival of dopamine cells. In a small group of patients... -
MJFF Research Grant, 2011Ghrelin Concentrations in CSF and Corresponding Serum Samples in PD Patients and Controls
Objective/Rationale:
The aim of this study is to establish a valid method for measuring ghrelin concentrations in human cerebrospinal fluid samples. Ghrelin is an appetite-stimulating hormone with... -
Non-pharmacological Interventions for Gait and Balance, 2019Protective Step Training in People with Parkinson's Disease and Postural Disturbances
Study Rationale:
Falls are a common and challenging symptom of Parkinson's disease. The ability to execute a quick and effective movement after a loss of balance (e.g., a "protective step") may reduce... -
Research Grant, 2020Alpha-synuclein Toxicity in LRRK2 Knock-in Models and Rescue by LRRK2 Silencing
Study Rationale:
Gene mutations that alter the function of the LRRK2 protein are known to increase the risk of developing Parkinson’s disease (PD). One of the pathological hallmarks of PD is the... -
Target Advancement Program, 2021Sex-based Modulation of Neuromelanin-linked Parkinson’s Disease Pathology
Study Rationale:
Parkinson’s disease (PD) is more common in men than in women, and men with PD exhibit earlier onset, faster progression, more severe motor symptoms and more frequent cognitive decline... -
Research Grant, 2022Development And Validation Of A Miro1 Biomarker Assay Using White Blood Cells
Study Rationale: The mitochondrial protein Miro1 fails to be degraded and this defect impairs mitophagy in more than 90% of all Parkinson’s disease (PD) patients of both genetic and sporadic forms...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.